Ipsen S.A. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
IPSEY Over the counter 2834 www.ipsen.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ipsen S.A.

Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma - Jan 21st, 2026 9:45 am
Galderma Provides Update on Arbitration Case Regarding Neuromodulator Research and Development Partnership - Jan 21st, 2026 9:35 am
Is Ipsen (ENXTPA:IPN) Pricing Fair After Strong Multi Year Share Price Gains - Jan 14th, 2026 4:08 am
New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS - Jan 13th, 2026 11:00 pm
U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia - Jan 13th, 2026 10:19 am
JPM26: Day 1 – drug prices and policy changes drive the agenda - Jan 13th, 2026 3:59 am
Ipsen - December 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital - Jan 7th, 2026 10:30 am
Ipsen – Half year statement – 2025 12 31 - Jan 6th, 2026 10:00 am
Ipsen (ENXTPA:IPN): Taking a Fresh Look at Valuation After a Year of Quiet Outperformance - Dec 24th, 2025 11:32 pm
Ipsen outlays $1bn for China-based Simcere’s preclinical ADC - Dec 23rd, 2025 5:53 am
Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate - Dec 21st, 2025 11:00 pm
Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP) - Dec 18th, 2025 11:00 pm
Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline - Dec 15th, 2025 9:30 am
Does Ipsen’s Governance Shift After Henri Beaufour’s Passing Alter the Bull Case for Ipsen (ENXTPA:IPN)? - Dec 10th, 2025 1:13 am
IPSEN - Buy-back programme - Art 5 of MAR - Week 49- 2025 - Dec 9th, 2025 10:00 am
Biotech Showcase™ 2026 Returns to San Francisco During JPM Week as a Premier Destination for Dealmakers - Dec 9th, 2025 8:00 am
Ipsen provides update on legacy of Henri Beaufour - Dec 4th, 2025 10:58 pm
IPSEN - Buy-back programme - Art 5 of MAR - Week 48 - 2025 - Dec 2nd, 2025 10:00 am
Ipsen mourns the passing of Henri Beaufour, a founding family Board member - Nov 30th, 2025 11:00 pm
Is Ipsen’s Acquisition the Catalyst for a Better Value in 2025? - Nov 28th, 2025 5:09 am